These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35063740)

  • 1. Ruthenium complexes boost NK cell immunotherapy via sensitizing triple-negative breast cancer and shaping immuno-microenvironment.
    Chen Q; He L; Li X; Xu L; Chen T
    Biomaterials; 2022 Feb; 281():121371. PubMed ID: 35063740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selenium-containing ruthenium complex synergizes with natural killer cells to enhance immunotherapy against prostate cancer via activating TRAIL/FasL signaling.
    Lai H; Zeng D; Liu C; Zhang Q; Wang X; Chen T
    Biomaterials; 2019 Oct; 219():119377. PubMed ID: 31374478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selenadiazole derivative-loaded metal azolate frameworks facilitate NK cell immunotherapy by sensitizing tumor cells and shaping immuno-suppressive microenvironments.
    Yang Y; Jiang Y; Xie B; Shi S; Pi F; Chen M; Sang C; Xu L; Chen T
    Biomater Sci; 2023 Feb; 11(4):1517-1529. PubMed ID: 36606484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Boosting Natural Killer Cell-Based Cancer Immunotherapy with Selenocystine/Transforming Growth Factor-Beta Inhibitor-Encapsulated Nanoemulsion.
    Liu C; Lai H; Chen T
    ACS Nano; 2020 Sep; 14(9):11067-11082. PubMed ID: 32806028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-Time Tracking of
    Uong TNT; Lee KH; Ahn SJ; Kim KW; Min JJ; Hyun H; Yoon MS
    Front Immunol; 2018; 9():825. PubMed ID: 29770131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells.
    Sommaggio R; Cappuzzello E; Dalla Pietà A; Tosi A; Palmerini P; Carpanese D; Nicolè L; Rosato A
    Oncoimmunology; 2020 Jun; 9(1):1777046. PubMed ID: 32923140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Click Chemistry-Mediated Polymannose Surface-Engineering of Natural Killer Cells for Immunotherapy of Triple-Negative Breast Cancer.
    Niu X; Yang H; Guo J; Yao L; Wang Y; Yu W; Liu Z; Chen H
    Adv Healthc Mater; 2024 Sep; 13(23):e2400970. PubMed ID: 38838184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gold-seaurchin based immunomodulator enabling photothermal intervention and αCD16 transfection to boost NK cell adoptive immunotherapy.
    Lin X; Li F; Gu Q; Wang X; Zheng Y; Li J; Guan J; Yao C; Liu X
    Acta Biomater; 2022 Jul; 146():406-420. PubMed ID: 35470078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The anti-cancer effect of series of strained photoactivatable Ru(II) polypyridyl complexes on non-small-cell lung cancer and triple negative breast cancer cells.
    Fayad C; Audi H; Khnayzer RS; Daher CF
    J Biol Inorg Chem; 2021 Feb; 26(1):43-55. PubMed ID: 33221954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxicity and anti-tumor effects of new ruthenium complexes on triple negative breast cancer cells.
    Popolin CP; Reis JPB; Becceneri AB; Graminha AE; Almeida MAP; Corrêa RS; Colina-Vegas LA; Ellena J; Batista AA; Cominetti MR
    PLoS One; 2017; 12(9):e0183275. PubMed ID: 28898246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
    Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?
    Ben-Shmuel A; Biber G; Barda-Saad M
    Front Immunol; 2020; 11():275. PubMed ID: 32153582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
    Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
    Front Immunol; 2020; 11():40. PubMed ID: 32082316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer.
    Hu Z
    Sci Rep; 2020 Feb; 10(1):2815. PubMed ID: 32071339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models.
    Greene S; Robbins Y; Mydlarz WK; Huynh AP; Schmitt NC; Friedman J; Horn LA; Palena C; Schlom J; Maeda DY; Zebala JA; Clavijo PE; Allen C
    Clin Cancer Res; 2020 Mar; 26(6):1420-1431. PubMed ID: 31848188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ELK3-CXCL16 axis determines natural killer cell cytotoxicity via the chemotactic activity of CXCL16 in triple negative breast cancer.
    Jung HY; Lee DK; Lee M; Choi SH; Park JD; Ko ES; Lee J; Park KS; Jung HY
    Oncoimmunology; 2023; 12(1):2190671. PubMed ID: 36950218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next Generation Immuno-Oncology Strategies: Unleashing NK Cells Activity.
    Mendoza-Valderrey A; Alvarez M; De Maria A; Margolin K; Melero I; Ascierto ML
    Cells; 2022 Oct; 11(19):. PubMed ID: 36231109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined NK Cell Therapy and Radiation Therapy Exhibit Long-Term Therapeutic and Antimetastatic Effects in a Human Triple Negative Breast Cancer Model.
    Kim KW; Jeong JU; Lee KH; Uong TNT; Rhee JH; Ahn SJ; Kim SK; Cho D; Quang Nguyen HP; Pham CT; Yoon MS
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):115-125. PubMed ID: 31605787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells.
    Ferreira-Teixeira M; Paiva-Oliveira D; Parada B; Alves V; Sousa V; Chijioke O; Münz C; Reis F; Rodrigues-Santos P; Gomes C
    BMC Med; 2016 Oct; 14(1):163. PubMed ID: 27769244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.